Actinium Pharmaceuticals Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-36374 ACTINIUM PHARMACEUTICALS, INC.(Exact name of registrant as specified in its charter) (646) 677-3870(Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days.☒YesNo☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files).☒Yes No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards, provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of May 7, 2026: 31,374,991 Actinium Pharmaceuticals, Inc. Table of ContentsINDEX PART I – FINANCIAL INFORMATIONItem 1.Financial Statements1Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosures About Market Risk38Item 4.Controls and Procedures38 PART II – OTHER INFORMATIONItem 1.Legal Proceedings39Item 1A.Risk Factors39Item 2.Unregistered Sales of Equity Securities and Use of Proceeds77Item 3.Defaults Upon Senior Securities77Item 4.Mine Safety Disclosures77Item 5.Other Information77Item 6.Exhibits78SIGNATURES79 PART I - FINANCIAL INFORMATION ITEM 1. UNAUDITED FINANCIAL STATEMENTS The accompanying condensed consolidated financial statements have been prepared by Actinium Pharmaceuticals, Inc., orthe Company, and are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments)necessary to present fairly the financial position at March 31, 2026 and December 31, 2025, and the results of operations and cashflows for the three months ended March 31, 2026 and 2025, respectively, have been made. Certain information and footnotedisclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in theUnited States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction withthe financial statements and notes thereto included in the Company’s audited financial statements for the year ended December 31,2025 in the Company’s Annual Report on Form 10-K. The results of operations for the three months ended March 31, 2026 are notnecessarily indicative of the operating results for the full year. (amounts in thousands, except share and per share data) Long-term license revenue deferred35,00035,000Long-term operating lease obligations785972Total Liabilities43,13443,941 Stockholders’ Equity:Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding--Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,374,991 and 31,195,891shares issued and outstanding, at March 31, 2026 and December 31, 2025, respectively3131Additional paid-in capital417,547417,536Accumulated other comprehensive loss(39)(20)Accumulated deficit(415,235)(409,713)Total Stockholders’ Equity2,3047,834 See accompanying notes to the condensed consolidated financial statements. (amounts in thousands, except share and per share data) (amounts in thousands) For theThree Months EndedMarch 31, Actinium Pharmaceuticals, Inc.Notes to Condensed Consolidated Financial Statements(Unaudited) Note 1 - Description of Business and Summary of Significant Accounting Policies Nature of Business- Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutic